Oasmia Pharmaceutical will publish its Year-end report for the shortened financial year May 1, 2020 – December 31, 2020 on February 19, 2021, at 08.00 am CET. The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet, CEO and Acting CFO Robert Maiorana. The presentation will be in English.

The conference call will be broadcast live on the web via the link:
https://tv.streamfabriken.com/oasmia-pharmaceutical-year-end-2020

Telephone number for the conference call is:
SE: +46856642706
UK: +443333009262
US: +18335268380

For more information: 
 
Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com
 
Consilium Strategic Communications 
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company’s proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar).  Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com